News & Press Releases
Sparrow Pharmaceuticals Expands Executive Leadership With Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality
Sparrow Pharmaceuticals announced the appointment of Frank Czerwiec, MD, PhD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and Quality. Dr. Czerwiec has more than 35 years of experience in industry, academia, and public service, while Dr. MacPherson brings her more than 20 years of experience as a regulatory affairs and quality assurance professional in the pharmaceutical and biotechnology industries across a wide variety of therapeutic areas.
Sparrow Pharmaceuticals Presents Data on SPI-62 at the European Congress of Endocrinology
Sparrow Pharmaceuticals presented new data at the European Congress of Endocrinology 2021 on 22-26 May 2021 as a poster presentation, “SPI-62: An investigational HSD-1 inhibitor for the treatment of Cushing syndrome”.
Sparrow Pharmaceuticals Secures $50 Million Series A Financing
Sparrow Pharmaceuticals announced the closing of a $50 million Series A financing. OrbiMed led the investment round with participation by RiverVest Venture Partners and U.S. Venture Partners (USVP).